The risk of death after the placement of a coronary stent remains a legitimate concern for patients and their loved ones. This interventional cardiology procedure, performed annually on a large number of patients in France and around the world, has seen its safety improve notably over the past two decades.
The adjusted mortality rate related to coronary procedures in the United States in 2023 represents less than one-third of that recorded in 1999, according to an analysis published by Alatfawy et al. in 2026. This structural trend deserves to be known, as the content available online tends to emphasize complications rather than this overall improvement.
Stent Thrombosis and Mortality: The Most Feared Mechanism
Among the complications that can lead to death after angioplasty, stent thrombosis holds a special place. It occurs when a blood clot forms inside the stent, abruptly blocking the artery that has just been treated. This phenomenon can cause a massive heart attack, sometimes fatal.
The distinction between early thrombosis and late thrombosis has direct implications for management. Early thrombosis manifests in the first few days following implantation, often related to a technical defect or poor expansion of the stent. Late thrombosis, on the other hand, can appear months or even years after placement, generally linked to premature cessation of antiplatelet therapy.
As shown by detailed analyses on Valbreon, several aggravating factors accumulate in certain patient profiles, making the prevention of this complication even more complex.
The type of stent implanted also plays a role. Drug-eluting stents, coated with a medication that limits local cell proliferation, reduce the risk of restenosis compared to bare-metal stents. However, they require a prolonged dual antiplatelet therapy to prevent late thrombosis, which exposes the patient to another risk: bleeding.
Duration of Dual Antiplatelet Therapy: A Trade-off Between Bleeding and Thrombosis
The post-stent treatment relies on the combination of two antiplatelet agents (typically aspirin and a P2Y12 inhibitor). The duration of this dual therapy is the subject of active medical debate, as it directly conditions the risk of death through two opposing pathways.
- A treatment that is too short increases the risk of stent thrombosis and heart attack, especially with first-generation drug-eluting stents.
- A treatment that is too long raises the risk of serious bleeding (digestive, cerebral), potentially fatal in elderly or frail patients.
- Recent European recommendations (ESC 2024 for chronic coronary artery disease) have shortened the standard duration of dual therapy for patients at high bleeding risk, allowing protocols of one to three months followed by monotherapy.
This evolution marks a turning point. Until now, the rule was often a twelve-month dual therapy, applied relatively uniformly. Now, the strategy is personalized according to the patient’s profile, which implies a rigorous assessment of the individual bleeding risk at the time of placement.
The Danger of Unsupervised Cessation of Treatment
One of the most documented factors of death remains the abrupt interruption of antiplatelet therapy, whether by personal decision of the patient, forgetfulness, or due to a scheduled non-cardiac surgery without coordination with the cardiologist. This scenario creates a window of vulnerability where the stent, not yet covered by the arterial wall, is exposed to the rapid formation of a thrombus.
Perioperative recommendations emphasize the necessity of never interrupting dual therapy without cardiological advice. When a surgical intervention is unavoidable, a bridging protocol must be established, and surgery postponed if possible beyond the critical period.
Patient-Related Risk Factors: Age, Diabetes, and Complex Lesions
The mortality after stent placement does not solely depend on the procedure itself. The patient’s background weighs heavily in the equation.
Diabetes is a recognized aggravating factor. Diabetic patients often present with more diffuse, more calcified coronary lesions, and a less favorable vascular response after implantation. The risk of restenosis and stent thrombosis is higher in this population.
Advanced age represents another determining parameter. Beyond 75 years, vascular fragility, multiple comorbidities (renal failure, history of stroke), and increased sensitivity to anticoagulants complicate post-intervention management. The available data do not allow for setting an age threshold beyond which stent placement would be contraindicated, but the benefit-risk ratio must be evaluated on a case-by-case basis.
Calcified coronary lesions pose a specific technical challenge. Rotational atherectomy, used to prepare heavily calcified arteries before stent implantation, improves the expansion of the prosthesis but adds a layer of procedural complexity. The outcomes largely depend on the experience of the interventional cardiology team.
Preventing Post-Stent Death: What Falls to the Patient and Medical Follow-Up
Prevention relies on two complementary pillars: adherence to treatment and the quality of cardiological follow-up.
On the patient side, strict adherence to antiplatelet therapy remains the most effective lever to reduce mortality. This requires a clear understanding of the stakes, transparent communication with the treating cardiologist, and the absence of self-medication (some anti-inflammatories interact with antiplatelet agents).
On the medical follow-up side, regular monitoring by the cardiologist allows for early detection of restenosis or progression of coronary artery disease in other arteries. Follow-up consultations, stress tests, and, in some cases, non-invasive coronary imaging constitute the tools for this vigilance.
- Immediately report any chest pain, unusual shortness of breath, or discomfort to the cardiologist.
- Never stop, reduce, or modify the dosage of antiplatelet treatment without prior medical advice.
- Inform any healthcare professional (dentist, surgeon, anesthetist) about the presence of a stent and ongoing treatment before any intervention.
- Adapt lifestyle: quit smoking, control cholesterol, engage in physical activity as recommended by the cardiologist.
The structural trend of decreasing mortality related to coronary procedures is encouraging, but it does not exempt individual vigilance. The stent treats a consequence of coronary artery disease, not its cause. Secondary prevention (treatment, lifestyle, follow-up) conditions long-term survival much more than the prosthesis itself.
